MedPath

Efficacy of 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenia syndrome

Not Applicable
Completed
Conditions
ambert-Eaton myasthenia syndrome
Registration Number
JPRN-jRCT1091220208
Lead Sponsor
Hiroyuki FUKUDA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
3
Inclusion Criteria

Clinically confirmed Lambert-Eaton myasthenia patients who have muscle weakness

Exclusion Criteria

Poor PS
GOT,GPT>100
BUN>30,Cr>2.0

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath